Non-interventional Study Describing Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)
Phase of Trial: Phase IV
Latest Information Update: 04 May 2017
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms SPAF
- Sponsors Boehringer Ingelheim
- 28 Apr 2017 Planned End Date changed from 1 Jul 2017 to 30 Oct 2017.
- 28 Apr 2017 Planned primary completion date changed from 1 Jul 2017 to 30 Oct 2017.
- 26 Jul 2016 New trial record